Abstract. The expression of amino acid transporter (AT) mRNAs including A system (ATA1/SNAT1/SLC38A1, ATA2/ SNAT2/SLC38A2 and ATA3/SNAT3/SLC38A4), L system (LAT1/SLC7A5 and LAT2/SLC7A8), and y + (CAT2/SLC7A2) genes, were compared among hepatocellular carcinoma (HCC) and non-cancerous liver cells. Among them the ATA1 mRNA expression was significantly elevated in all HCC cell lines (HepG2, HLF, HuH7 and JHH4) examined compared with normal liver tissue. We further discovered that the expression of ATA1 mRNA was significantly activated in HCC tissues and also elevated in pre-malignant cirrhotic livers from HCC patients, compared with normal livers from non-HCC patients. The ATA1 protein was extensively accumulated in the cytoplasm of pre-malignant liver and most HCCs, while being weak or undetectably low in normal liver tissues. SiRNAmediated suppression of endogenous ATA1 lowered the viability of HepG2 cells. Thus, the activation of ATA1 confers growth and survival advantages in pre-malignant and malignant liver lesions.
Introduction
Amino acids are required for a wide variety of important biological processes including malignant transformation in mammalian cells. Indeed, most cells activate various different systems that are required for amino acid transport (1) . Among these systems, the system L-type amino acid transporter-1 (LAT-1) is up-regulated in human bladder carcinoma cells (2) , esophageal adenocarcinoma (3), epidermoid carcinoma (4), oral squamous cell carcinoma (5) and liver cancer (6) . On the other hand, another of the major amino acid transport systems, system A, catalyses the transport of most of the small aliphatic amino acids including alanine, serine and glutamine (1) . System A gene activity is dependent on cellular growth in many cell types, and increases in chemically and virally transformed cells (1) . Moreover, physiological liver hyperplasias, including those that occur during pregnancy, lactation and fetal and neonatal development, are mainly associated with increased system A activity (1) .
There are three known system A gene isoforms which primarily differ by their tissue expression patterns. ATA1 is primarily expressed in the neurons in the brain and spinal cord, but is not observed in lung, liver, spleen or kidney (7) . ATA2 is ubiquitously expressed in every tissue (8) , and ATA3 is expressed almost exclusively in the liver (9) . Among these genes, ATA2 activity is induced in regenerating livers (10, 11) . In carcinomas, the estrogen-dependent activation of system A is observed in breast cancers (12) . Furthermore, inherent differences in the system A carrier are observed between normal and transformed liver tissues (13) . On the other hand, L-arginine is an essential rate-limiting nutrient for the survival of different tumor cells, which cannot synthesize this amino acid (14) . The y + cationic amino acid transporter genes (CAT1, 2 and 3) encode the transporters that mediate most arginine uptake in mammalian cells (1) .
In our present study, we analyzed the expression of several amino acid transporter genes, including those of system L, A and y + in hepatocellular carcinoma cells, and our data demonstrate the physiological importance of ATA1 in hepatocarcinogenesis.
Materials and methods
Tissue specimens and HCC cell lines. Surgically resected HCC and adjacent non-cancerous liver tissues from 25 patients, in addition to five normal liver tissue controls, were used in the RT-PCR analyses in this study. The viral status of the HCC patients was classified as 15 HCV positive, 2 HBV positive, and 8 non-B non-C. In addition, each of our HCC patients had suffered from liver cirrhosis. For immunohistochemical analysis, we examined a different series of 15 paraffin-embedded HCC and adjacent liver tissues, and 2 normal liver tissues (Table I) . All of these studies were performed with the informed consent of each patient and with the permission of the ethics committee of the National were normalized to the expression levels of the ß2M transcript. To evaluate the statistical significance of the differentially expressed genes, a Welch's t-test (two-sided) was performed. We performed the direct sequencing analyses and observed that each PCR product was correctly amplified (not shown).
Production of polyclonal antibodies against human ATA1.
An oligopeptide (DWACSSSSDEGHC) corresponding to amino acid residues 476-487 of the human ATA1 protein was synthesized. C-terminal cysteine residue was used for conjugation with keyhole limpet hemocyanin. Anti-peptide antibody was then produced as described elsewhere (17) and the antiserum was affinity purified as described previously (18) .
Immunohistochemical analysis. Immunohistochemical analysis of the ATA1 protein was performed using the avidin-biotinperoxidase complex method. Briefly, for antigen retrieval, the sections were treated with 0.5% trypsin at 37˚C for 10 min. After blocking with 1% skim milk, tissue sections were then incubated with anti-ATA1 polyclonal antibody (1:200) overnight at 4˚C, then washed in phosphate-buffered saline solution. Biotinylated anti-rabbit IgG was used as the secondary antibody. The specificity of this antibody was confirmed using blocking experiments with the ATA1 synthetic peptide.
Small interfering RNA analysis. Two pairs of anti-ATA1 siRNAs were commercially obtained (Takara), 5'-GGA UGA UAA CAU UAG CAA UTT-3' and 5'-AUU GCU AAU GUU AUC AUC CTT-3' for HDCK-ATA1, and 5'-GGA Table I . Immunohistochemical analysis of ATA1 in HCC and non-cancerous liver tissues.
Liver histology and HCC grading Relative ATA1 expression 
a B, HBV; C, HCV; NBNC, non-B non-C; nd, not determined.
b LC, liver cirrhosis; CAH, chronic active hepatitis. na, not applicable.
GAU AAA GGA ACU CAA ATT-3' and 5'-UUU GAG UUC CUU UAU CUC CTT-3' for DFIEX-ATA1. For transfection of these molecules, 5x10 4 HepG2 cells were seeded in 24-well plates. One hundred pmol of specific siRNAs or randomized cocktails of dsRNA as a control was then mixed with 8 μl of the Trans IT-TKO transfection reagent (Mirus Bio Corporation) and 53 μl of DMEM (without FBS). After incubation for 15 min at room temperature, the mixture was diluted to 300 μl with DMEM (10% FBS) and added to the cells which were cultured for a further 12 h. The cells were then harvested and gene expression inhibition was assessed by quantitative RT-PCR, as described previously (16), using two different ATA1-specific primer pairs (529F/679R; 5'-CAA TGA CTC CAA TGA TTT CAC CGA-3' and 5'-CAT GCC TAA GGA GGT TGT ACC TGG-3') and (1677F/1827R; 5'-TGA TCT TCA TAC CCT CCA TGA AGG-3' and 5'-GAA AAG GGC AGC CCA AAT TCT T-3').
Cell viability assay. To determine the viability of siRNAtransfected cells, the redox activity of viable cells was measured using an XTT [2,3-bis (2-methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilide] assay. Briefly, 2x10
5 cells/ml (0.1 ml aliquots) were inoculated into a 96-well microtiter plates in triplicate. Thereafter, transfections were performed as described above except that 300 μl of the diluted mixture was divided into triplicate wells. After 24, 48 and 72 h, 50-μl aliquots of a solution containing 1 mg/ml of XTT (Sigma) and 10 μM of phenazine methylsulfate (Sigma) were added to each well. The plates were then incubated for a further 2 h at 37˚C to allow color development, and the absorbance was measured at 492 nm. A relative survival ratio was calculated based on the absorbance values, measured in triplicate, from standard wells without cells.
Results

Expression of AT mRNAs in HCC cell lines.
To analyze the expression of the AT genes including A system (ATA1/ SNAT1/SLC38A1, ATA2/SNAT2/SLC38A2 and ATA3/SNAT3/ SLC38A4), L system (LAT1/SLC7A5 and LAT2/SLC7A8), and y + (CAT2/SLC7A2) in HCC cells, we examined their expression in HCC cell lines. As shown in Fig. 1 , the levels of ATA1 mRNA were 15-to 30-fold higher in four HCC cell lines tested (HLF, JHH4, HuH7 and HepG2) compared with the normal liver tissue. The levels of ATA2 and LAT1 mRNAs were found to be moderately elevated in some of the HCC cell lines compared with the normal liver samples. The levels of CAT2 and ATA3 transcripts varied among the HCC cell lines but showed no significant differences compared with normal liver tissue. The expression of LAT2 was observed to be at almost undetectable levels both in the normal liver tissue and each of the HCC cell lines. Thus, among the ATs examined, the expression of ATA1 mRNA was significantly activated in each of four separate HCC cell lines.
The expression of amino acid transporter mRNAs in normal and pre-cancerous liver tissues, and in HCC. We further examined the expression of ATA1, ATA2 and LAT1 mRNAs in 25 HCCs and pre-cancerous liver tissues from the same patients, as well as in five normal liver tissues from non-HCC patients, respectively. As shown in Fig. 2 , the expression of the ATA1 mRNA was significantly activated in HCC tissues (average ± SE; 8.38±2.69) compared with normal liver tissues (1.79±1.17) from non-HCC patients (p=0.026). Interestingly, the ATA1 mRNA expression was also upregulated in non-cancerous cirrhotic livers (NLs) from HCC patients (6.36±1.41); however the expression in NLs was averagely lower than in adjacent HCCs. The expression levels of the ATA2 mRNA were significantly higher in NLs (7.44±1.39) than in normal livers (2.57±0.28) or in HCCs (4.62±0.73). On the other hand, the expression of LAT1 mRNA showed no significant difference among HCCs, precancerous and normal livers (Fig. 2) . We also confirmed that the expression levels of ATA1 mRNA in non-cancerous and HCC tissues were unaffected by the viral status (HCV, HBV or non-A non-B) (data not shown).
Immunohistochemical analysis of the ATA1 protein product in both non-cancerous liver and HCC tissues.
To examine the expression of the ATA1 gene product in vivo, we next performed a series of immunohistochemical analyses. As shown in Fig. 3 , in normal liver tissue the expression of ATA1 protein was very low or undetectable around the perivenous area, and was very weakly expressed in the cytoplasm of the parenchymal cells in the periportal area (Fig. 3A and B) . ATA1 expression was also undetectable in the fibroblastic non-parenchymal cells. In contrast, the cytoplasmic ATA1 protein levels showed markedly increased expression levels in well-differentiated HCC and adjacent cirrhotic liver tissues (Fig. 3C, D and E) . It is noteworthy also that a marked accumulation of ATA1 was observed in the micro-bile ducts of cirrhotic liver samples (Fig. 3E arrow) , and on the luminal sides of pseudo-bile duct structures in well-differentiated HCC tissues (Fig. 3D arrow) . High levels of cytoplasmic ATA1 were also observed in both moderately ( Fig. 3F and G) , and poorly differentiated ( Fig. 3H and I ) HCCs. We further examined the ATA1 protein levels in an additional panel of 15 HCC samples and matched non-cancerous liver tissues and detected substantial levels of expression in each of the non-cancerous liver specimens from individuals suffering from either cirrhosis or hepatitis. These expression levels were significantly elevated in five, and were similar in a further six HCCs, compared with the matched pre-cancerous livers (Table I) . ATA1 expression was found to be very low in the remaining four HCC samples in this cohort (Table I) . Among these tissues, no particular correlation could be found between the histological tumor grades and ATA1 protein levels. Taken together, our data show therefore that the ATA1 protein levels are markedly up-regulated in pre-cancerous and cancerous liver tissues compared with normal liver.
Functional significance of ATA1 activation in HCC.
Our results using both cell lines and tissues demonstrated that the expression of ATA1 was prominently activated in HCCs and also in pre-cancerous liver lesions. To assess the functional significance of ATA1 activation in HCC, we performed siRNA knockdowns of endogenous ATA1 transcripts in the HepG2 cells. To reduce the possibility of off-target effects, these cells were transfected with two independently designed ATA1-specific siRNAs, denoted HDCK and DFI, respectively. Compared to the randomized dsRNA cocktail control, both the HDCK and DFI siRNAs were found to significantly reduce the endogenous ATA1 transcript levels to <10% and <17.5%, respectively, of the normal control 12 h after transfection (Fig. 4A) . As shown in Fig. 4B , the viability of the DFI transfectants was reduced to 79.0% on day 2, and was further reduced to 64.4% on day 3. In a similar fashion, the cell viability of the HDCK-transfectants was reduced to 68.0 and 55.0% on days 2 and 3, respectively. Since these two independent siRNA molecules exerted very similar effects on cell viability, we conclude that the activation of the ATA1 gene in HCC cells confers a growth or survival advantage.
Discussion
Our findings indicate that the expression of amino acid transporter genes, ATA1 and ATA2, are activated in cancerousand pre-cancerous liver tissues in patients suffering from cirrhosis and/or hepatitis, but remained at lower levels in normal liver tissue from non-HCC patients. Analogous to our present observations, a neural amino acid transporter, ATB 0 , has also been shown previously to be overexpressed in cirrhotic liver samples (19) . It has been further reported that the activity of ATA2 (20, 21) is adaptively up-regulated in response to physiological changes such as nutrient starvation. Since the cellular requirements for amino acids including L-arginine are increased during liver cirrhosis and fibrosis (22) (23) (24) , the elevation of AT mRNAs in precancerous livers may thus also be attributable to nutrient starvation.
Our results demonstrate that the expression of ATA1 and ATA2 was, in general, elevated in pre-cancerous liver tissue in patients suffering from hepatitis and/or cirrhosis compared with normal liver tissues. However, in HCC tissues, these expression patterns varied; the expression of ATA1 mRNA was averagely elevated, while ATA2 mRNA was reduced in HCCs compared with pre-cancerous livers in HCC patients. These results suggest that the regulatory mechanisms underlying AT expression are quite diverse during the pre-malignant to malignant transition in liver cells. We also confirmed that ATA1 mRNA was highly activated in four separate HCC cell lines cultured in standard growth media, suggesting that the elevated expression of ATA1 is not simply due to an adaptive response such as nutrient starvation in HCC cells but rather a tumor-specific mechanism. System A amino acid transporters mediate the Na + -coupled transport of neutral amino acids including alanine, serine and glutamine (1, 25) . Among the three system A isoforms that have been characterized, ATA1 Figure 2 . Expression of ATA1, ATA2, and LAT1 mRNAs in five normal livers (normal), 25 HCCs and matched non-cancerous liver tissues. Total RNA extracts from these tissues were subjected to QRT-PCR as described (16) . The relative mRNA expression levels were then calculated by normalizing with a ß 2 -microglobulin control. Each circle represents a patient sample. Bars denote average expression levels. NL, non-cancerous livers; HCC, hepatocellular carcinomas.
has the highest affinity for glutamine (26) , is strongly expressed in glutamatergic neurons, and has been suggested to participate in the cycling of glutamate and glutamine transportation between astrocytes and glial cells (7, 27) . In normal fetal and adult hepatocytes, the uptake of glutamine is mainly mediated by system N (7) or, potentially by ATA3 as mentioned above. Although, ATA1 is primarily expressed in neurons, and not in normal liver (7), our results demonstrate that its expression is significantly elevated both in HCC tissues and HCC cell lines. In this regard, it is noteworthy that since tumors use glutamine as a primary metabolic fuel and nitrogen source (28, 29) , a marked depletion of plasma glutamine occurs in patients with liver cancer (30) . Hence, such an ectopic activation of ATA1 may be a compensatory amino acid uptake mechanism that confers a survival advantage in HCC cells.
Our histological observations demonstrate that the ATA1 protein is only marginally expressed around the periportal area in the normal liver but that its cytoplasmic expression is significantly enhanced both in pre-malignant and malignant liver lesions. Interestingly, a marked accumulation of ATA1 Representative tissues in C, D and E correspond to specimen 7; F, G to specimen 5; and H, I to specimen 11 in Table I, respectively. was also observed in micro-bile ducts in pre-cancerous cirrhotic liver and also on the luminal side of the pseudo-bile duct structure in HCC tissues. However, the functional significance of the localization of ATA1 has yet to be elucidated.
Our knockdown experiments using anti-ATA1 siRNAs successfully reduced the expression of endogenous ATA1 transcripts to <18% of the control cell levels. These siRNA experiments also reduced the viability of HepG2 cells, suggesting that the ATA1 molecule is a requisite for tumor survival. However, the viability of siRNA-treated HepG2 cells still remained higher than we had expected (>55%) given the significantly reduced mRNA levels (<17.5%). HCC cells may thus have compensatory mechanisms for specific amino acid uptake. In fact, it is known that a neutral amino acid transporter, ATB 0 is activated in HCC cells and promotes glutamine-dependent tumor growth (19) .
In conclusion therefore, future investigations that are designed to further understand both the functional significance and the regulatory mechanisms underlying amino acid transporters could provide diagnostic and therapeutic insights into hepatocarcinogenesis. 
